Literature DB >> 23329430

Acknowledging patient heterogeneity in economic evaluation : a systematic literature review.

Janneke P C Grutters1, Mark Sculpher, Andrew H Briggs, Johan L Severens, Math J Candel, James E Stahl, Dirk De Ruysscher, Albert Boer, Bram L T Ramaekers, Manuela A Joore.   

Abstract

BACKGROUND AND
OBJECTIVE: Patient heterogeneity is the part of variability that can be explained by certain patient characteristics (e.g. age, disease stage). Population reimbursement decisions that acknowledge patient heterogeneity could potentially save money and increase population health. To date, however, economic evaluations pay only limited attention to patient heterogeneity. The objective of the present paper is to provide a comprehensive overview of the current knowledge regarding patient heterogeneity within economic evaluation of healthcare programmes.
METHODS: A systematic literature review was performed to identify methodological papers on the topic of patient heterogeneity in economic evaluation. Data were obtained using a keyword search of the PubMed database and manual searches. Handbooks were also included. Relevant data were extracted regarding potential sources of patient heterogeneity, in which of the input parameters of an economic evaluation these occur, methods to acknowledge patient heterogeneity and specific concerns associated with this acknowledgement.
RESULTS: A total of 20 articles and five handbooks were included. The relevant sources of patient heterogeneity (demographics, preferences and clinical characteristics) and the input parameters where they occurred (baseline risk, treatment effect, health state utility and resource utilization) were combined in a framework. Methods were derived for the design, analysis and presentation phases of an economic evaluation. Concerns related mainly to the danger of false-positive results and equity issues.
CONCLUSION: By systematically reviewing current knowledge regarding patient heterogeneity within economic evaluations of healthcare programmes, we provide guidance for future economic evaluations. Guidance is provided on which sources of patient heterogeneity to consider, how to acknowledge them in economic evaluation and potential concerns. The improved acknowledgement of patient heterogeneity in future economic evaluations may well improve the efficiency of healthcare.

Entities:  

Mesh:

Year:  2013        PMID: 23329430     DOI: 10.1007/s40273-012-0015-4

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  41 in total

1.  Optimisation versus certainty: understanding the issue of heterogeneity in economic evaluation.

Authors:  Warren Stevens; Charles Normand
Journal:  Soc Sci Med       Date:  2004-01       Impact factor: 4.634

2.  Recognising diversity in public preferences: the use of preference sub-groups in cost-effectiveness analysis. A response to Sculpher and Gafni.

Authors:  Angela Robinson; David Parkin
Journal:  Health Econ       Date:  2002-10       Impact factor: 3.046

3.  Pharmacogenomics and the evolution of healthcare : is it time for cost-effectiveness analysis at the individual level?

Authors:  Mohan V Bala; Gary A Zarkin
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

4.  Reflecting heterogeneity in patient benefits: the role of subgroup analysis with comparative effectiveness.

Authors:  Mark Sculpher
Journal:  Value Health       Date:  2010-06       Impact factor: 5.725

5.  Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation.

Authors:  Peter M Rothwell
Journal:  Lancet       Date:  2005 Jan 8-14       Impact factor: 79.321

6.  Does pharmacogenomics provide an ethical challenge to the utilisation of cost-effectiveness analysis by public health systems?

Authors:  Adam La Caze
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

7.  Value of information on preference heterogeneity and individualized care.

Authors:  Anirban Basu; David Meltzer
Journal:  Med Decis Making       Date:  2007 Mar-Apr       Impact factor: 2.583

8.  Methods for incorporating covariate adjustment, subgroup analysis and between-centre differences into cost-effectiveness evaluations.

Authors:  Richard M Nixon; Simon G Thompson
Journal:  Health Econ       Date:  2005-12       Impact factor: 3.046

Review 9.  Design and analysis issues for economic analysis alongside clinical trials.

Authors:  Deborah A Marshall; Margaret Hux
Journal:  Med Care       Date:  2009-07       Impact factor: 2.983

10.  Shared treatment decision making in a collectively funded health care system: possible conflicts and some potential solutions.

Authors:  Mark Sculpher; Amiram Gafni; Ian Watt
Journal:  Soc Sci Med       Date:  2002-05       Impact factor: 4.634

View more
  24 in total

1.  Exploring Uncertainty in Economic Evaluations of Drugs and Medical Devices: Lessons from the First Review of Manufacturers' Submissions to the French National Authority for Health.

Authors:  Salah Ghabri; Françoise F Hamers; Jean Michel Josselin
Journal:  Pharmacoeconomics       Date:  2016-06       Impact factor: 4.981

2.  Characterizing Heterogeneity Bias in Cohort-Based Models.

Authors:  Elamin H Elbasha; Jagpreet Chhatwal
Journal:  Pharmacoeconomics       Date:  2015-08       Impact factor: 4.981

3.  Healthy decisions: towards uncertainty tolerance in healthcare policy.

Authors:  Janneke P C Grutters; Marjolein B A van Asselt; Kalipso Chalkidou; Manuela A Joore
Journal:  Pharmacoeconomics       Date:  2015-01       Impact factor: 4.981

Review 4.  Challenges in modelling the cost effectiveness of various interventions for cardiovascular disease.

Authors:  Laura T Burgers; William K Redekop; Johan L Severens
Journal:  Pharmacoeconomics       Date:  2014-07       Impact factor: 4.981

5.  Economic Evaluation of Vaccination Programmes in Older Adults and the Elderly: Important Issues and Challenges.

Authors:  Sevan Dirmesropian; James G Wood; C Raina MacIntyre; Philippe Beutels; Anthony T Newall
Journal:  Pharmacoeconomics       Date:  2016-08       Impact factor: 4.981

Review 6.  Hepatocellular Carcinoma: Etiology and Current and Future Drugs.

Authors:  Aastha Jindal; Anusha Thadi; Kunwar Shailubhai
Journal:  J Clin Exp Hepatol       Date:  2019-01-25

7.  Multistate Statistical Modeling: A Tool to Build a Lung Cancer Microsimulation Model That Includes Parameter Uncertainty and Patient Heterogeneity.

Authors:  Mathilda L Bongers; Dirk de Ruysscher; Cary Oberije; Philippe Lambin; Carin A Uyl-de Groot; V M H Coupé
Journal:  Med Decis Making       Date:  2015-03-02       Impact factor: 2.583

Review 8.  Patient Variability Seldom Assessed in Cost-effectiveness Studies.

Authors:  Tara A Lavelle; David M Kent; Christine M Lundquist; Teja Thorat; Joshua T Cohen; John B Wong; Natalia Olchanski; Peter J Neumann
Journal:  Med Decis Making       Date:  2018-01-19       Impact factor: 2.583

9.  Direct Medical Costs of Advanced Breast Cancer Treatment: A Real-World Study in the Southeast of The Netherlands.

Authors:  Paul Peter Schneider; Bram L Ramaekers; Xavier Pouwels; Sandra Geurts; Khava Ibragimova; Maaike de Boer; Birgit Vriens; Yes van de Wouw; Marien den Boer; Manon Pepels; Vivianne Tjan-Heijnen; Manuela Joore
Journal:  Value Health       Date:  2021-02-13       Impact factor: 5.725

10.  Preliminary investigation of economics issues in hospitalized patients with stroke.

Authors:  Zahra Tolou-Ghamari; Vahid Shaygannejad; Fariborz Khorvash
Journal:  Int J Prev Med       Date:  2013-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.